Abeona Therapeutics Inc. (0H7R.L)
USD 5.88
(-2.0%)
USD 5.88
(-2.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -48.2 Million USD | -6.5% |
| 2022 | -45.25 Million USD | 21.11% |
| 2021 | -57.37 Million USD | -18.28% |
| 2020 | -48.5 Million USD | 37.08% |
| 2019 | -77.09 Million USD | -32.53% |
| 2018 | -58.16 Million USD | -108.96% |
| 2017 | -27.83 Million USD | -16.56% |
| 2016 | -23.88 Million USD | -31.42% |
| 2015 | -18.17 Million USD | -480.36% |
| 2014 | -3.13 Million USD | 17.69% |
| 2013 | -3.8 Million USD | 11.86% |
| 2012 | -4.31 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -17.86 Million USD | -24.66% |
| 2024 Q1 | -14.33 Million USD | -8.49% |
| 2023 Q3 | -11.33 Million USD | 2.45% |
| 2023 FY | -48.2 Million USD | -6.5% |
| 2023 Q2 | -11.61 Million USD | 3.48% |
| 2023 Q4 | -13.2 Million USD | -16.54% |
| 2023 Q1 | -12.03 Million USD | -0.43% |
| 2022 FY | -45.25 Million USD | 21.11% |
| 2022 Q3 | -9.38 Million USD | 0.93% |
| 2022 Q2 | -9.46 Million USD | 34.35% |
| 2022 Q1 | -14.42 Million USD | -1.67% |
| 2022 Q4 | -11.98 Million USD | -27.78% |
| 2021 Q2 | -13.71 Million USD | 6.04% |
| 2021 Q4 | -14.18 Million USD | 4.61% |
| 2021 Q3 | -14.87 Million USD | -8.44% |
| 2021 Q1 | -14.59 Million USD | -0.81% |
| 2021 FY | -57.37 Million USD | -18.28% |
| 2020 Q3 | -6.24 Million USD | 49.94% |
| 2020 Q2 | -12.48 Million USD | 18.4% |
| 2020 FY | -48.5 Million USD | 37.08% |
| 2020 Q1 | -15.29 Million USD | 6.8% |
| 2020 Q4 | -14.48 Million USD | -131.75% |
| 2019 Q2 | -23.97 Million USD | -25.83% |
| 2019 Q4 | -16.41 Million USD | 7.01% |
| 2019 Q3 | -17.64 Million USD | 26.39% |
| 2019 FY | -77.09 Million USD | -32.53% |
| 2019 Q1 | -19.05 Million USD | -5.8% |
| 2018 Q1 | -10.68 Million USD | -22.09% |
| 2018 Q3 | -16.91 Million USD | -34.71% |
| 2018 Q4 | -18.01 Million USD | -6.47% |
| 2018 FY | -58.16 Million USD | -108.96% |
| 2018 Q2 | -12.55 Million USD | -17.54% |
| 2017 Q3 | -5.36 Million USD | 36.47% |
| 2017 Q2 | -8.44 Million USD | -59.73% |
| 2017 Q1 | -5.28 Million USD | 9.4% |
| 2017 FY | -27.83 Million USD | -16.56% |
| 2017 Q4 | -8.75 Million USD | -63.19% |
| 2016 Q3 | -5.17 Million USD | 22.95% |
| 2016 FY | -23.88 Million USD | -31.42% |
| 2016 Q4 | -5.83 Million USD | -12.72% |
| 2016 Q2 | -6.71 Million USD | -9.01% |
| 2016 Q1 | -6.16 Million USD | 1.49% |
| 2015 Q4 | -6.25 Million USD | -1.44% |
| 2015 Q2 | -4.12 Million USD | -106.14% |
| 2015 Q1 | -2 Million USD | -328.69% |
| 2015 FY | -18.17 Million USD | -480.36% |
| 2015 Q3 | -6.16 Million USD | -49.36% |
| 2014 FY | -3.13 Million USD | 17.69% |
| 2014 Q4 | -467 Thousand USD | 26.22% |
| 2014 Q2 | -703 Thousand USD | 47.06% |
| 2014 Q3 | -633 Thousand USD | 9.96% |
| 2014 Q1 | -1.32 Million USD | -94.15% |
| 2013 FY | -3.8 Million USD | 11.86% |
| 2013 Q1 | -503 Thousand USD | 58.74% |
| 2013 Q2 | -1.92 Million USD | -281.91% |
| 2013 Q3 | -696 Thousand USD | 63.77% |
| 2013 Q4 | -684 Thousand USD | 1.72% |
| 2012 FY | -4.31 Million USD | 0.0% |
| 2012 Q4 | -1.21 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | 71.51% |
| Dynavax Technologies Corporation | -37.02 Million USD | -30.172% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -814.785% |
| Perrigo Company plc | 151.9 Million USD | 131.731% |
| Illumina, Inc. | -1.06 Billion USD | 95.491% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 100.703% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 89.534% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 99.658% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 102.438% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 56.425% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 101.191% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -7.91% |
| Waters Corporation | 817.67 Million USD | 105.895% |
| Biogen Inc. | 1.29 Billion USD | 103.717% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 82.409% |
| Evolus, Inc. | -49.23 Million USD | 2.098% |
| Adicet Bio, Inc. | -152.03 Million USD | 68.297% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 60.328% |
| bluebird bio, Inc. | -244.26 Million USD | 80.267% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 69.016% |
| FibroGen, Inc. | -281.81 Million USD | 82.897% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 103.57% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -6.927% |
| Homology Medicines, Inc. | -48.25 Million USD | 0.114% |
| Geron Corporation | -193.94 Million USD | 75.147% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 82.918% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 34.416% |
| Myriad Genetics, Inc. | -123.7 Million USD | 61.035% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 52.195% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 90.646% |
| Zoetis Inc. | 3.06 Billion USD | 101.571% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 104.433% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 124.789% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 101.119% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -23.107% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 86.374% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 82.537% |
| Verastem, Inc. | -92.08 Million USD | 47.656% |
| Nektar Therapeutics | -137.42 Million USD | 64.926% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 79.208% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 50.491% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 82.003% |
| OPKO Health, Inc. | -157.02 Million USD | 69.303% |
| Exelixis, Inc. | 170.88 Million USD | 128.206% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 119.211% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 144.928% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 13.552% |
| uniQure N.V. | -282.87 Million USD | 82.96% |
| Imunon, Inc. | -21.03 Million USD | -129.192% |
| Blueprint Medicines Corporation | -486.27 Million USD | 90.088% |
| Insmed Incorporated | -709.62 Million USD | 93.208% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 114.278% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 87.688% |
| TG Therapeutics, Inc. | 20.63 Million USD | 333.606% |
| Incyte Corporation | 620.52 Million USD | 107.768% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 93.365% |